MARCoNS, Alpha-MSH and CIRS: What New Research Reveals About Mold Illn

People suffering from Chronic Inflammatory Response Syndrome (CIRS), mold illness, and toxic mold exposure often ask whether MARCoNS treatment really matters. A newly published study suggests the answer may be yes.

Researchers recently reported that CIRS patients who successfully cleared MARCoNS had significantly higher levels of alpha-melanocyte stimulating hormone (α-MSH), an important neuroimmune regulatory peptide frequently found at low levels in people with Chronic Inflammatory Response Syndrome.

The findings provide new evidence that the nasal microbiome may play an important role in recovery from CIRS and mold-related illness.

What is MARCoNS?

MARCoNS (Multiple Antibiotic-Resistant Coagulase-Negative Staphylococci) are bacteria that can colonize the nasal passages and sinuses. These bacteria are capable of forming protective biofilms, allowing them to persist despite the body's immune defenses and many conventional treatment approaches.

Many practitioners working with Chronic Inflammatory Response Syndrome (CIRS) consider MARCoNS an important factor because these biofilms may contribute to persistent inflammation and impaired recovery.

For years, clinicians treating mold illness and CIRS have observed that patients often improve after successfully addressing MARCoNS. Until recently, however, there has been limited published research examining the relationship between MARCoNS status and recovery of key biological markers.

What is Alpha-MSH?

Alpha-MSH (alpha-melanocyte stimulating hormone) is a neuroimmune regulatory peptide involved in controlling inflammation, supporting barrier function, regulating pain perception, and helping maintain healthy sleep patterns.

Low alpha-MSH levels are commonly reported in patients with Chronic Inflammatory Response Syndrome and are often associated with symptoms such as:

Brain fog
Chronic fatigue
Sleep disturbances
Increased pain sensitivity
Persistent inflammation

Because alpha-MSH influences multiple systems throughout the body, it has become one of the most closely monitored biomarkers within the CIRS framework.

The Study: Following CIRS Patients Over Time

The study, published in Frontiers in Endocrinology, followed 188 adults being evaluated and treated within a Chronic Inflammatory Response Syndrome framework.

Researchers examined changes in MARCoNS status alongside three commonly monitored biomarkers:

Alpha-MSH

A neuroimmune regulatory peptide involved in inflammation control and overall immune balance.

VIP (Vasoactive Intestinal Polypeptide)

A signaling molecule involved in neurological, immune, and inflammatory regulation.

MMP-9 (Matrix Metalloproteinase-9)

An inflammatory marker often elevated during periods of increased tissue remodeling and systemic inflammation.

Importantly, participants were receiving comprehensive CIRS-directed care rather than treatment focused solely on MARCoNS. The researchers therefore evaluated whether MARCoNS status was associated with biomarker recovery within the broader treatment process.

The Big Finding: MARCoNS Clearance Was Selectively Associated with Higher Alpha-MSH

Across the entire patient population, overall health markers generally moved in a positive direction over time. MMP-9 levels decreased while both VIP and alpha-MSH showed upward trends.

However, a particularly interesting pattern emerged when researchers compared patients who successfully cleared MARCoNS with those who remained MARCoNS-positive.

Patients who tested negative for MARCoNS at follow-up demonstrated significantly higher circulating alpha-MSH levels than patients who continued to test positive for MARCoNS.

What makes this finding especially noteworthy is its specificity.

While VIP and MMP-9 improved over time, their changes were not significantly associated with MARCoNS status. Alpha-MSH was the only biomarker that showed a significant relationship with successful MARCoNS clearance.

If MARCoNS status were simply reflecting overall improvement, we might expect all three biomarkers to behave similarly. Instead, only alpha-MSH demonstrated a significant association, suggesting a potentially unique connection between nasal microbial colonization and melanocortin signaling.

Why This Matters for CIRS and Mold Illness

Alpha-MSH helps regulate inflammatory signaling throughout the body. Research has shown that it influences cytokine activity, supports epithelial barrier function, and helps modulate pain processing.

When alpha-MSH levels are low, inflammatory pathways may become less effectively regulated. Many practitioners believe this contributes to symptoms commonly experienced by people with Chronic Inflammatory Response Syndrome, including fatigue, cognitive difficulties, sleep disturbances, and chronic pain.

This new research provides some of the strongest quantitative evidence to date that persistent MARCoNS colonization may be linked to impaired alpha-MSH recovery in individuals undergoing treatment for CIRS.

The findings also reinforce growing interest in the nasal microbiome as a potential contributor to systemic immune and neuroendocrine health.

Important Study Limitations

As with any retrospective observational study, these findings do not prove that MARCoNS directly causes low alpha-MSH levels.

The study demonstrates a significant association between MARCoNS clearance and higher alpha-MSH levels, but additional prospective studies will be needed to determine whether MARCoNS actively influences alpha-MSH production or whether successful MARCoNS clearance simply reflects broader improvements occurring during treatment.

Nevertheless, the findings provide compelling support for further investigation into the relationship between MARCoNS, the nasal microbiome, alpha-MSH, and Chronic Inflammatory Response Syndrome.

The Takeaway

For individuals dealing with Chronic Inflammatory Response Syndrome, mold illness, or toxic mold exposure, this study provides additional support for the importance of evaluating the nasal microbiome as part of a comprehensive recovery strategy.

The most intriguing finding was not simply that patients improved over time, but that alpha-MSH recovery appeared uniquely associated with successful MARCoNS clearance. This suggests that what happens inside the nasal passages may have far-reaching effects on immune and neuroendocrine function throughout the body.

BioFilm Clear's nasal sprays are designed to support a healthy nasal microbiome. The formula contains EDTA, an ingredient widely studied for its ability to disrupt biofilms, along with other carefully selected ingredients intended to help maintain a balanced nasal environment.

While additional research is needed, studies such as this continue to highlight the potential importance of the nasal microbiome in overall immune, inflammatory, and neuroendocrine health.

Frequently Asked Questions

What is MARCoNS?

MARCoNS stands for Multiple Antibiotic-Resistant Coagulase-Negative Staphylococci, a group of biofilm-forming bacteria that can colonize the nasal passages and sinuses.

Can MARCoNS lower alpha-MSH?

This study found that patients who successfully cleared MARCoNS had significantly higher alpha-MSH levels than those who remained MARCoNS-positive. However, the study does not prove that MARCoNS directly causes low alpha-MSH.

What is alpha-MSH?

Alpha-MSH is a neuroimmune regulatory peptide involved in inflammation control, sleep regulation, pain modulation, and barrier function.

Why is alpha-MSH important in CIRS?

Many patients with Chronic Inflammatory Response Syndrome have low alpha-MSH levels, which may contribute to symptoms such as fatigue, brain fog, sleep disturbances, and chronic inflammation.

What role does the nasal microbiome play in CIRS?

Emerging research suggests that bacteria living in the nasal passages may influence immune function, inflammatory signaling, and neuroendocrine regulation throughout the body.